Skip to main content
. 2022 Sep 7;23(18):10336. doi: 10.3390/ijms231810336

Table 1.

Classification of endogenous and pharmacological molecules targeting NMDARs.

Endogenous Molecules Pharmacological Molecules
Channel blockers and modulators:
Mg2+ [1]
Neurosteroids [8]		 Channel blockers and modulators:
MK-801 [9]
Aptiganel [10]
Dextromethorphan [11]
Amantadine [12]
Memantine [13]
Ketamine [13]
Methadone [14]
Dimebon [15]
Agonists:
Glutamate [16]
Glycine/D-serine [17]
L-Theanine [18]
Glycine/Glutamate site antagonists:
Polyamines [19]
Zn2+; Cu2+ [20]		 Glycine/Glutamate site antagonists:
Selfotel [21]
Rapastinel [22]
NYX-2925 [23]
Apimostinel [24]
Gavestinel [25]
AV-101 [26]
Phencyclidine [27]
PAMs and NAMs:
Spermines and Spermidines [19]
Cholesterol [28]
Pregnelonone sulfate [29]
ATP [30]		 PAMs and NAMs:
SAGE-718 [31]
NP10679 [19]
Neu2000 [32,33]
Downstream antagonist:
Uric acid [34]		 Downstream antagonists:
Nerinetide [35]
AVLX-144 [36]
ARG-007 [37]
ZL006 [38]
Tramiprosate [39]
Edaravone Dexborneol [40]
Tat-CAPON and ZLc-002 [41]
Bpv and Tat-K13 [42,43]
Modulators:
amyloid-β (Aβ) [44]
tPA [45]		 Antibody:
Glunomab [46]